Proposal 1 Do you agree with the proposal to report Traded Options when matched on the market data feed LMEselectMD?

Similar documents
CABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND

Background EVM. FAO/WHO technical workshop on nutrient risk assessment, Geneva, May 2005, published 2006.

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

EUROPEAN COMMISSION. Modus Operandi for the management of new food safety incidents with a potential for extension involving a chemical substance

Hearing aid dispenser approval process review Introduction Hearing aid dispenser data transfer... 6

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations

Professional Conduct Department User Satisfaction Survey of Complainants and Barristers. Annual Report 2010

The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,

Summary of responses: Consultation on determining the amount of a variable monetary penalty. April 2017

Medical Devices. UKRAINE Magisters

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW. Summary Record of Meeting of 15 July 2009

SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section General Food Law)

The Welsh Government will ask people in health and social services to:

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

The legal basis of this draft Regulation is Art. 11 (4) of Regulation (EC) No. 882/2204.

EHR Developer Code of Conduct Frequently Asked Questions

UNITED STATES OF AMERICA BEFORE THE FEDERAL ENERGY REGULATORY COMMISSION. Portland General Electric Company ) Docket No.

ACCESS TO DENTAL CARE FOR BRISTOL STUDENTS

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

Re: May 2018 Consultation Paper, Professional Skepticism Meeting Public Expectations

Exhibit 2 RFQ Engagement Letter

RE: IESBA s Exposure Draft Proposed Revisions Pertaining to Safeguards in the Code Phase 1

Comments on Consultative Report Governance arrangements for critical OTC derivatives data elements (other than UTI and UPI)

Board Meeting Date of Meeting: Wednesday 3 rd May, 2017

Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

BACKGROUND + GENERAL COMMENTS

15 May 2017 Exposure Draft. Response Due Date 23 June Exposure Draft

Annual Report 2005 of the Mortality Forum

EUROPEAN COMMISSION SUMMARY REPORT OF THE STANDING COMMITTEE ON PLANTS, ANIMALS, FOOD AND FEED HELD IN BRUSSELS ON 07 MARCH 2017

British Columbia Data Standards

GOOD PHARMACOPOEIAL PRACTICES

Mānuka Honey Labelling Guidelines Work Group and Science Work Group Meeting Summary

Consistency in REC Review

Fiona Campbell. ISA 315 (Revised) Responding to Comments to the Exposure Draft. Deputy Chair of the IAASB and Chair of the ISA 315 Task Force

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

(Text with EEA relevance) (2014/798/EU)

ARTEMIS. An integrated review service for radioactive waste and spent fuel management, decommissioning and remediation programmes

Education and Training Committee 15 November 2012

QUESTIONS: GENERAL. 2. Would it then be fair to say that TCF carries a lot of (confusing) duplication?

General Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.

Response to. GPhC Consultation. Guidance to ensure a safe and effective pharmacy team.

RESPONSE TO CESR S CONSULTATION PAPER ON POSSIBLE IMPLEMENTING MEASURES CONCERNING STORAGE AND FILING OF REGULATED INFORMATION (CESR /06-025)

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

This memo includes background of the project, the major themes within the comments, and specific issues that require further CSAC/HITAC action.

Choose a fertility clinic: update

Global Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488

EUROPEAN COMMISSION SUMMARY REPORT OF THE STANDING COMMITTEE ON PLANTS, ANIMALS, FOOD AND FEED HELD IN BRUSSELS ON 09 JUNE 2015

Tenant & Service User Involvement Strategy

REPORT FROM THE COMMISSION TO THE COUNCIL. on Directive 2011/64/EU on the structure and rates of excise duty applied to manufactured tobacco

Yorkshire and the Humber Kidney Transplant Forum NOTES

Frailty: Messages from the consultation by the Older People s Commission for Wales

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

BE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA

Support to paediatric medicines development

VETERINARY SERVICES ACT (CAP. 437) Use and Marketing of Enzymes, Micro-organisms and their Preparations in Animal Nutrition Rules, 2006

Involvement of people affected

Knowledge-Based Decision-Making (KBDM) to reach an Informed Group Conscience

Changes to Australian Government Hearing Services Program and Voucher scheme

Medicare Physician Fee Schedule Final Rule for CY 2018 Appropriate Use Criteria for Advanced Diagnostic Imaging Services Summary

IMPORTANT DISCLAIMER. Note

Working Document prepared by the Commission services - does not prejudice the Commission's final decision 3/2/2014 COMMISSION STAFF WORKING DOCUMENT

Business Impact Analysis

USPSTF Draft Recommendations Investor Call. October 6, 2015

10.2 Summary of the Votes and Considerations for Policy

Self-regulatory proposal from the european alcoholic beverages sectors on the provision of nutrition information and ingredients listing

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report

Enhanced Service for people with dementia in Primary Care

Consultative report. Committee on Payments and Market Infrastructures. Board of the International Organization of Securities Commissions

Study Reveals Consumer Knowledge of Government Regulations

The call for compulsory hygiene rating displays for food outlets in England.

LEAF Marque. Standard Setting. Public System Report

SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD ON DECEMBER 2009 IN BRUSSELS (Section Animal Nutrition)

Staff Flu Campaign Evaluation Tool

Author s response to reviews

Basis for Conclusions: ISA 530 (Redrafted), Audit Sampling

Challenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection

PROVIDER CONTRACT ISSUES

STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW. Summary Record of Meeting of 30 April 2012

Comparison Report For Kathryn Petersen Working with Martin Gilmore

JICPA comments on the IESBA Exposure Draft, Proposed Revisions to the Code Pertaining to the Offering and Accepting of Inducements

Price Correction Report Week of Nov 28- Dec 2, 2016

Primer: Medical Device User Fee Amendments Han Zhong l September 2011

Young Farmers Clubs of Ulster. Club Leader Role Description and Guidelines

Critical Review Form Clinical Decision Analysis

Ministry of Children and Youth Services. Independent Clinical Review Process for the Ontario Autism Program. Guidelines

SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE

Sheep Health Statement (SHS) Frequently Asked Questions

The Performance Evaluation of Re-Circulating. Air LEV Systems

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

Business Requirements Definition. Project Nexus

Price Correction Report Week of November 26 November 30, 2018, 2017

THE RESPONSIBLE PHARMACIST REGULATIONS

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE

ECB-PUBLIC OPINION OF THE EUROPEAN CENTRAL BANK. of 11 April on a proposal for a regulation on the establishment of the European Monetary Fund

Falsified Medicines Directive - Safety Features Update

Regulatory incentives: Experience from European Medicines Agency

Transcription:

Appendix 1 Summary of Feedback and Responses Proposal 1 Do you agree with the proposal to report Traded Options when matched on the market data feed LMEselectMD? Respondent 1 The respondent is in favour of this proposal. Noted. Yes Respondent 2 The respondent is generally in favour of this proposal but would like clarification on two points: 1. The respondent has concerns over the timescale for the implementation of the new reporting regime and has requested details of the reporting window far in advance of the implementation date. 2. The respondent would also like clarification that this proposal will only be for Member-to-Member trades. The LME acknowledges the respondent s comments and provides the following clarity on the two points raised: 1. The LME will provide at least three months notice before any agreed changes are implemented. 2. For consistency, the proposal to report Traded Options on the LME market data feed (LMEselectMD) will include Client trades. This is in addition to Member-to-Member trades for both the Inter-office and LMEselect trading venues. A similar approach will be taken with the proposal to report Futures trades, which will additionally include Ring business. Yes/No Respondent 3 The respondent is in favour of this proposal. Noted. Yes Respondent 4 The respondent agrees with the rationale to report transactions for Traded Options when they are matched on a real-time basis. However, the respondent s preference is to exclude Client trades from these reports. The LME acknowledges the respondent s comments. The LME believes that the inclusion of reporting Client transactions for both Futures and Options on a real-time basis, which is consistent with the proposal to report Member-to-Member transactions, will provide market participants with a more comprehensive and structured Yes/No

transparency regime for the LME. This in turn may promote and incentivise more participation on the LME. The LME would like to reiterate that Client and Member trades will not be displayed separately on the LME market data feed and there will be no trade-type identifier. Therefore, while there will be greater market transparency, it will not be possible to tell whether the reported trade is derived from a Client or Member. Respondent 5 The respondent is in favour of this proposal. The respondent references a previous correspondence from them to the LME and reiterates that Client accountability should be the same as it is for Members. The LME acknowledges the comments of the respondent. The LME would also like to further clarify that the proposal to publish transactions for Traded Options on the LME market data feed includes Client and Member trades for both Futures and Options on a real-time basis. The LME believes that this will provide a higher level of consistency and transparency for all market participants. Yes Respondent 6 The respondent is supportive in establishing a consistent approach to transaction reporting, but given client feedback received, believes further consideration is required to find a suitable solution at a time when the value of the LME client contract is being questioned. The LME acknowledges the comments of the respondent, but must consider under MiFID II it will be obliged to report transactions on a real-time basis. The LME believes that the inclusion of reporting Client transactions for both Futures and Options on a real-time basis, which is consistent with the proposal to report Member-to-Member transactions, will provide market participants with a more comprehensive and structured transparency regime for the LME. This in turn may promote and incentivise more participation on the LME. No

Respondent 7 The respondent has requested confirmation of the level of trade detail that will be published in the real time reporting of Traded Options. The respondent has expressed a request for a level of protection in favour of Market Makers, removing the Vol and Price of trades from the reports. The LME acknowledges the respondent s comments and would like to clarify that the following trade details will be reported: Trade Time, Metal, Description, Price and Size. The LME believes that a level of protection will be provided to Market Makers in the form of deferred publication of large trades. Proposal 2 Do you agree with the proposal to remove the logic to defer the reporting of large trades by 2 business days? Respondent 1 The respondent strongly supports this proposal. Noted. Yes Respondent 2 The respondent states that they have a preference to remain with the current logic of deferring large in scale trades for two business days. The respondent does note, however, that under new regulations for MiFID II this may not be possible. The respondent concludes that, until the new regulatory requirements are clarified, they feel that large trades should continue to be deferred for two business days. The LME acknowledges the respondent s comments. The LME will apply to the FCA for a waiver to enable it to keep the deferral for large in scale trades if it resolved through this consultation that this should be the way forward. At this stage the final details of deferrals permitted under MiFID II have yet to be clarified. No

Respondent 3 The respondent does not agree with the proposal to remove the logic to defer the reporting of large trades. The respondent further comments that the LME and Traded Options Committee spent considerable time debating and implementing the deferred publication of large trades. Therefore, the removal of this logic may question why it was introduced originally. The respondent also indicates that the current method protects the market makers position in a market which is not particularly liquid. The LME acknowledges the respondent s comments. If the LME does intend to continue with deferred publication under MiFID II, it will need to apply for a waiver from the FCA to continue with this method of reporting Options transactions that are large in scale. It will, however, be likely that the LME will still be required to publish price and instrument on the relevant trade day at 7.00 pm, with the volume being deferred until around 7.00 pm after two business days. No Respondent 4 The respondent is in favour of this proposal. Noted. Yes Respondent 5 The respondent does not agree with the proposal to remove the logic to defer the reporting of large trades. The respondent makes reference to previous discussions around the introduction of the deferred publication of large trades, and the subsequent amendments to the definition of large in scale trades. While the process originally deemed anything over 100 lots as a large trade, these thresholds were then adjusted following discussions with the Traded Options Committee. The respondent questions the LME s rationale in proposing to remove the deferred publication of large trades after only one year and asks for The LME notes the respondent s comments. The LME acknowledges that the introduction of this process arose from discussions within the Traded Options Committee and other market participants. The LME would like to note that when the deferral of large in scale trades was introduced, the full implications of regulatory change around this reporting methodology were unclear at the time. However, through discussions with market participants it was felt prudent to carry on with this reporting regime until a more suitable methodology could be considered at the appropriate opportunity. Through this consultation, the LME welcomes comments from market participants on this issue so the LME can gauge general views and opinions. The LME No

clarification on this. does have the ability to request a waiver from the FCA, although the exact details of any deferral that may be granted are unclear at this stage. Respondent 6 The respondent has no comment. Noted. Respondent 7 The respondent has no comment. Noted. Proposal 3 Do you agree with the proposal to decommission the batched Options Matched Trades reports? Respondent 1 The respondent supports this proposal and has requested that the LME works with Bloomberg to ensure that their LMPM page collates the realtime data correctly and in a timely manner. The LME notes these comments and is working closely with Bloomberg and other market data vendors to ensure that all relevant reports for Options matched trade data will be published correctly and in the appropriate format. Yes Respondent 2 The respondent supports this proposal. Noted. Yes Respondent 3 The respondent supports this proposal. Noted. Yes

Respondent 4 The respondent supports this proposal. Noted. Yes Respondent 5 The respondent has no comment. Noted. Respondent 6 The respondent has no comment. Noted. Respondent 7 The respondent has no comment. Noted. Proposal 4 Do you agree with the proposal to publish Options Open Interest on the next business day? Respondent 1 The respondent supports this proposal. Noted. Yes Respondent 2 The respondent supports this proposal but has a preference to remain with the current methodology of publishing Open Interest for large trades after two business days. The LME acknowledges the respondent s comments but would also state that from previous discussions a large proportion of market participants are in favour for the reporting of Options Open Interest on the next business day as this gives greater transparency particularly leading up to the relevant options expiry. Yes/No

Respondent 3 The respondent supports this proposal. Noted. Yes Respondent 4 The respondent is in favour of this proposal. Noted. Yes Respondent 5 The respondent has no comment. Noted. Respondent 6 The respondent has no comment. Noted. Respondent 7 The respondent has no comment. Noted. Proposal 5 Do you agree with the proposal to report Client Futures when matched on the market data feed LMEselectMD? Respondent 1 The respondent supports this proposal. Noted. Yes Respondent 2 The respondent supports this proposal. Noted. Yes

Respondent 3 The respondent supports this proposal. Noted. Yes Respondent 4 The respondent supports this proposal. Noted. Yes Respondent 5 The respondent has no comment. Noted. Respondent 6 The respondent has no comment. Noted. Respondent 7 The respondent has no comment. Noted. Proposal 6 Are there any other matters which you believe the Exchange should take into account in relation to the Proposals? Respondent 1 The respondent confirms their earlier point and has requested that the LME work with Bloomberg to ensure that the LMEO (Open Interest) and the LMPM pages are set up correctly and can display the data being sent by the LME in a timely and precise manner. The LME notes these comments and acknowledges the respondent s comments. The LME is already in constructive dialogue with Bloomberg and will work closely to ensure a successful implementation, if adopted. Yes

Respondent 2 The respondent has concerns over the number of reporting changes for LME products which is a burden on their internal resources. The respondent s view is that the LME should be focussing more on reviewing their settlement process. However, the respondent acknowledges that if these proposed changes are agreed as a result of general discussion and the views of the Trading Options Committee, then they will be implemented. The respondent emphasises that any reporting changes are clarified to the market and that the advanced notice of implementation is made transparent to the whole market. The LME notes and acknowledges the respondent s comments around the large number of reporting changes. However, the LME is looking to take a structured and comprehensive approach with the Proposals in this consultation which it believes will ultimately be more consistent and easier to digest for all market participants. In addressing the comments on settlement procedures, the LME has recently issued a decision notice on four enhancements that it believes will strengthen and enhance the determination of the Closing Prices for Traded Options. The LME also believes the procedures used both on the Ring and electronically for the determination of Futures Reference Prices are robust. The LME has introduced a number of rule and procedural changes both before and after the Board review of the Ring in 2014 that have strengthened the methodology for establishing both the Official and Closing Prices. Yes Respondent 3 The respondent indicates that they feel the LME should apply for a waiver to the FCA in order to allow the deferral of large trades to continue. The LME acknowledges the respondent s comments and any decision on applying for the waiver will come after the conclusion of this consultation. Respondent 4 The respondent has no further comment at this time. Noted.

Respondent 5 The respondent has no further comment at this time. Noted. Respondent 6 The respondent has no further comment at this time. Noted. Respondent 7 The respondent has no further comment at this time. Noted.